放疗与免疫治疗：协同增效。
Radiation and immunotherapy: a synergistic combination.
机构信息
Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
出版信息
J Clin Invest. 2013 Jul;123(7):2756-63. doi: 10.1172/JCI69219. Epub 2013 Jul 1.
Abstract
Immunotherapy can be an effective treatment for metastatic cancer, but a significant subpopulation will not respond, likely due to the lack of antigenic mutations or the immune-evasive properties of cancer. Likewise, radiation therapy (RT) is an established cancer treatment, but local failures still occur. Clinical observations suggest that RT may expand the therapeutic reach of immunotherapy. We examine the immunobiologic and clinical rationale for combining RT and immunotherapy, two modalities yet to be used in combination in routine practice. Preclinical data indicate that RT can potentiate the systemic efficacy of immunotherapy, while activation of the innate and adaptive immune system can enhance the local efficacy of RT.
摘要
免疫疗法可为转移性癌症提供有效的治疗手段，但相当一部分患者对此没有反应，其原因可能是缺乏抗原突变或肿瘤的免疫逃避特性。同样，放射疗法（RT）是一种已确立的癌症治疗方法，但仍会出现局部复发。临床观察表明，RT 可能会扩大免疫疗法的治疗范围。我们研究了 RT 和免疫疗法联合应用的免疫生物学和临床原理，这两种方法尚未在常规实践中联合使用。临床前数据表明，RT 可以增强免疫疗法的全身疗效，而固有和适应性免疫系统的激活可以增强 RT 的局部疗效。
相似文献
1
Radiation and immunotherapy: a synergistic combination.放疗与免疫治疗：协同增效。
J Clin Invest. 2013 Jul;123(7):2756-63. doi: 10.1172/JCI69219. Epub 2013 Jul 1.
2
Radiation-induced bystander and abscopal effects: important lessons from preclinical models.辐射诱导的旁观者效应和远隔效应：临床前模型的重要启示。
Br J Cancer. 2020 Aug;123(3):339-348. doi: 10.1038/s41416-020-0942-3. Epub 2020 Jun 25.
3
Targeting Innate Immunity to Enhance the Efficacy of Radiation Therapy.靶向固有免疫以提高放射治疗的疗效。
Front Immunol. 2019 Jan 14;9:3077. doi: 10.3389/fimmu.2018.03077. eCollection 2018.
4
Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors.双抗体疗法利用先天抗肿瘤免疫反应增强抗体对肿瘤的靶向作用。
Curr Opin Immunol. 2015 Apr;33:1-8. doi: 10.1016/j.coi.2014.12.010. Epub 2015 Jan 7.
5
The Impact of Radiation Therapy on Innate and Adaptive Tumor Immunity.放疗对固有和适应性肿瘤免疫的影响。
Semin Radiat Oncol. 2020 Apr;30(2):139-144. doi: 10.1016/j.semradonc.2019.12.005.
6
Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy.用于癌症治疗的联合疗法，包括疫苗、化疗和单克隆抗体。
Cancer Immunol Immunother. 2009 Mar;58(3):317-24. doi: 10.1007/s00262-008-0576-4. Epub 2008 Aug 15.
7
Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies.协同癌症免疫疗法将 MVA-CD40L 诱导的先天和适应性免疫与肿瘤靶向抗体结合在一起。
Nat Commun. 2019 Nov 6;10(1):5041. doi: 10.1038/s41467-019-12998-6.
8
Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy: Going Beyond Local Control.放射治疗联合免疫治疗的临床前理论依据与临床考量：超越局部控制
Cancer J. 2016 Mar-Apr;22(2):130-7. doi: 10.1097/PPO.0000000000000181.
9
Radiotherapy and immunotherapy: a beneficial liaison?放疗与免疫治疗：有益的联合？
Nat Rev Clin Oncol. 2017 Jun;14(6):365-379. doi: 10.1038/nrclinonc.2016.211. Epub 2017 Jan 17.
10
Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.针对免疫检查点受体和分子的自然杀伤细胞治疗调节。
Front Immunol. 2018 Sep 10;9:2041. doi: 10.3389/fimmu.2018.02041. eCollection 2018.
引用本文的文献
1
CD8-positive lymphocyte infiltration as a marker of anti-tumor immune response in rectal cancer: pre- and post-neoadjuvant radiotherapy comparison.CD8 阳性淋巴细胞浸润作为直肠癌抗肿瘤免疫反应的标志物：新辅助放疗前后的比较
Clin Transl Radiat Oncol. 2025 Jul 16;54:101018. doi: 10.1016/j.ctro.2025.101018. eCollection 2025 Sep.
2
Efficacy and safety of first-line chemoimmunotherapy in young patients with extensive-stage small cell lung cancer: a multicenter retrospective study.一线化疗免疫疗法在广泛期小细胞肺癌年轻患者中的疗效与安全性：一项多中心回顾性研究
BMC Cancer. 2025 Jul 1;25(1):1136. doi: 10.1186/s12885-025-14524-y.
3
Research progress on tumor-infiltrating lymphocyte therapy for cervical cancer.宫颈癌肿瘤浸润淋巴细胞治疗的研究进展
Front Immunol. 2025 May 19;16:1524842. doi: 10.3389/fimmu.2025.1524842. eCollection 2025.
4
Advancements in bladder cancer treatment: The synergy of radiation and immunotherapy.膀胱癌治疗的进展：放射疗法与免疫疗法的协同作用。
Oncotarget. 2025 May 19;16:337-346. doi: 10.18632/oncotarget.28723.
5
Tumour and microenvironment crosstalk in NSCLC progression and response to therapy.非小细胞肺癌进展及对治疗反应中的肿瘤与微环境相互作用
Nat Rev Clin Oncol. 2025 May 16. doi: 10.1038/s41571-025-01021-1.
6
Anti-Tumor Effects of Cecropin A and Drosocin Incorporated into Macrophage-like Cells Against Hematopoietic Tumors in Mutants.将天蚕素A和果蝇抗菌肽导入巨噬细胞样细胞对突变体造血肿瘤的抗肿瘤作用
Cells. 2025 Mar 7;14(6):389. doi: 10.3390/cells14060389.
7
Progress in immunotherapy for brain metastatic melanoma.脑转移性黑色素瘤免疫治疗的进展
Front Oncol. 2025 Jan 28;14:1485532. doi: 10.3389/fonc.2024.1485532. eCollection 2024.
8
Neoadjuvant chemoradiotherapy up-regulates PD-L1 in radioresistant colorectal cancer.新辅助放化疗上调放射抵抗性结直肠癌中的程序性死亡受体配体1（PD-L1）。
Clin Transl Radiat Oncol. 2024 Dec 22;51:100906. doi: 10.1016/j.ctro.2024.100906. eCollection 2025 Mar.
9
Salvage Reirradiation with Proton Beam Therapy for Locoregionally Recurrent Non-Small Cell Lung Cancer.质子束治疗对局部区域复发性非小细胞肺癌的挽救性再照射
Cancers (Basel). 2024 Oct 24;16(21):3587. doi: 10.3390/cancers16213587.
10
Prognosis of colorectal cancer, prognostic index of immunogenic cell death associated genes in response to immunotherapy, and potential therapeutic effects of ferroptosis inducers.结直肠癌的预后、免疫治疗反应相关免疫原性细胞死亡的预后指标，以及铁死亡诱导剂的潜在治疗效果。
Front Immunol. 2024 Sep 20;15:1458270. doi: 10.3389/fimmu.2024.1458270. eCollection 2024.
本文引用的文献
1
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.嵌合抗原受体修饰的 T 细胞治疗急性淋巴细胞白血病。
N Engl J Med. 2013 Apr 18;368(16):1509-1518. doi: 10.1056/NEJMoa1215134. Epub 2013 Mar 25.
2
Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.抗 PD-1 阻断和立体定向放疗可使颅内神经胶质瘤小鼠长期存活。
Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):343-9. doi: 10.1016/j.ijrobp.2012.12.025. Epub 2013 Feb 22.
3
Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletion.疫苗接种部位持续存在的抗原诱导肿瘤特异性 CD8+T 细胞隔离、功能障碍和缺失。
Nat Med. 2013 Apr;19(4):465-72. doi: 10.1038/nm.3105. Epub 2013 Mar 3.
4
Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma.TLR7 激动剂的全身给药与放射联合用于淋巴瘤小鼠模型中可诱导持久的抗肿瘤免疫反应。
Blood. 2013 Jan 10;121(2):251-9. doi: 10.1182/blood-2012-05-432393. Epub 2012 Oct 18.
5
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.单次剂量环磷酰胺后，IMA901 癌症疫苗的多肽免疫反应与患者更长的生存时间相关。
Nat Med. 2012 Aug;18(8):1254-61. doi: 10.1038/nm.2883. Epub 2012 Jul 29.
6
Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma.放化疗诱导食管鳞癌患者肿瘤细胞免疫原性死亡。
Cancer Res. 2012 Aug 15;72(16):3967-76. doi: 10.1158/0008-5472.CAN-12-0851. Epub 2012 Jun 14.
7
Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses.立体定向体部放疗和白细胞介素 2 的 1 期研究——肿瘤和免疫反应。
Sci Transl Med. 2012 Jun 6;4(137):137ra74. doi: 10.1126/scitranslmed.3003649.
8
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.抗 PD-1 抗体在癌症中的安全性、活性和免疫相关性。
N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2.
9
The abscopal effect associated with a systemic anti-melanoma immune response.与全身性抗黑色素瘤免疫反应相关的远隔效应。
Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):293-5. doi: 10.1016/j.ijrobp.2012.03.017. Epub 2012 May 5.
10
The three main stumbling blocks for anticancer T cells.抗肿瘤 T 细胞的三大障碍。
Trends Immunol. 2012 Jul;33(7):364-72. doi: 10.1016/j.it.2012.02.006. Epub 2012 Mar 23.
Zotero 插件